Hey all,
It didn't look good at first as straight away I saw 0.006 and wasn't happy. Took me a while to get over that! Here's some bad and good points from today's 2 announcements I was thinking about today, and then a comparison with another ASX biotech that was in a similar position to DXB 12 months ago.
Bad points:
- Still can't figure out why they raised capital now when they may be able to raise at a higher level over the next 6 months or so. Maybe they can't be taken seriously overseas with less than $1m cash?
- 0.006 is a low price compared to where it spiked 6 months ago but still reasonable given wwap over the last month or so.
- No mention of a cornerstone investor taking up any of the 333m shares, but we may see a s.603 or s.604 notice soon after 4th Feb – would need someone to breach about 90m shares (5%) for this to happen. May also see a change of sub holder which will show whether the 2 big guys put money in or were diluted from not doing so.
- So important whether the 333m shares have gone to holders in for the long haul or those happy to sell at 0.007, 0.008, 0.009 etc for a quick profit. Dimerix only traded about 700m shares for the whole of the last 12 months so will be hard to get through 333m shares!
Good points:
- 333m shares is not too much dilution compared to what the NDF research report was suggesting which was 1 billion shares at 1c. I don't believe currently there is much extra the company can do with $10m than it could do with $3m, so a good result imo. NDF research report target prices need to be updated to reflect this raise.
- The preso to investors mentions 1.5-2m to be raised so they have clearly had interest at the higher level (also confirmed in the 1st annc today).
- Once the dust settles Dimerix will be in a much better position with enough cash for people to forget about any more cap raisings in the short term.
- Importantly, todays preso shows the top holders have not sold any shares in the period from October except for J&L Peterson who look like they’ve sold just 3m shares.
- Todays preso highlighted that the interim update showed strong evidence of safety and likely efficacy.
- Also some new statements in the preso re opportunities for big pharma deals (Chemocentryx – Dec 2016)
- Something I hadn’t noticed before, very interestingly Dimerix own patent #….450 which seems to cover the very drug that Chemocentryx is developing. I am gonna check this to confirm.
What is everyone else thinking?
I had a look back at Innates history over the last 12 months and couldn't help notice some similarities between Dimerix and where Innate was 12 months ago. Here's the 2 presentations, Innates is from April 2016:
Innate:
http://www.asx.com.au/asxpdf/20160418/pdf/436l29g99hrkrn.pdf
Dimerix:
http://www.asx.com.au/asxpdf/20170125/pdf/43fj1gdjszshbr.pdf
Yes they are obviously targeting different disease groups but some key similarities are:
- Both companies targeting an unmet need
- Innate started from a low market cap, Dimerix is low now.
- Innate had around $3m cash at March 2016 prior to the share price taking off, DXB will have around $2.7m at Feb
- Similar potential annual market revenue being targeted - DXB US$3-5b, Innate - US$4b
- Both in phase 2, with strong recruitment patient interest
- "Strong evidence of safety and likely efficacy" – both presentations state this exact phrase
- Major pharma involved early for both companies
- Both with strong intellectual property focus
- Similar shareholder structure in both, – 1 major shareholder holding over 20% and top 20 shareholders holding just over 50%
Anyway, finally this was a new part of the presentation today that I thought was very important, worth taking note of:
- Forums
- ASX - By Stock
- DXB
- Analysis of the presentation today
Analysis of the presentation today
-
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $211.7M |
Open | High | Low | Value | Volume |
38.0¢ | 38.0¢ | 37.0¢ | $246.4K | 658.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 262775 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 32276 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 195263 | 0.370 |
12 | 1397167 | 0.365 |
6 | 59089 | 0.360 |
3 | 52619 | 0.355 |
9 | 102527 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 32276 | 2 |
0.385 | 30000 | 1 |
0.390 | 25524 | 3 |
0.395 | 161740 | 3 |
0.400 | 141398 | 5 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |